Arthritis care & research · 2026
Real-world safety of concomitant colchicine and statin therapy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Meidan Roni, Loutati Ranel, Caspi Dan, Elkayam Ori, Abuhasira Ran, Eviatar Tali
Аннотация
OBJECTIVE: This study aimed to evaluate the risk of clinically meaningful muscle- and liver-related outcomes associated with concomitant colchicine-statin therapy in a real-world setting, and to determine whether concomitant therapy increases the incidence of toxicity compared with either agent alone.
METHODS: A retrospective cohort study using the national Clalit Health Services database (≈5.4 million insured individuals). Adults with gout or familial Mediterranean fever between 2010 and 2024 were categorized into four exposure groups: no treatment, colchicine only, statin only, or concomitant therapy. Propensity-score matching was used to balance baseline characteristics. The primary outcome was creatine kinase (CK) elevation >3× the upper limit of normal (ULN), while secondary outcomes included alanine transaminase (ALT) elevation >5× the ULN, myopathy, liver disease, and hospitalizations related to these conditions.
RESULTS: Eligible participants before and after propensity-score matching were 104,066 and 31,839, respectively (no treatment n=7,146; colchicine only n=7,146; statin only n=9,030; concomitant therapy n=8,517). Compared with no treatment, CK elevations >3× ULN were observed with statin therapy (HR 1.64, 95% CI 1.39-1.93) and concomitant colchicine-statin therapy (HR 1.74, 95% CI 1.44-2.09), but not with colchicine therapy alone (HR 1.08, 95% CI 0.89-1.31). Clinically diagnosed myopathy was infrequent and showed a graded increase across exposure groups, with the highest risk observed in the concomitant treatment group (HR 1.50, 95% CI 1.31-1.72).
CONCLUSION: Although colchicine-statin concomitant therapy was associated with higher rates of laboratory and clinical adverse events, the additional risk beyond statin monotherapy was small, supporting their use when clinically indicated.
METHODS: A retrospective cohort study using the national Clalit Health Services database (≈5.4 million insured individuals). Adults with gout or familial Mediterranean fever between 2010 and 2024 were categorized into four exposure groups: no treatment, colchicine only, statin only, or concomitant therapy. Propensity-score matching was used to balance baseline characteristics. The primary outcome was creatine kinase (CK) elevation >3× the upper limit of normal (ULN), while secondary outcomes included alanine transaminase (ALT) elevation >5× the ULN, myopathy, liver disease, and hospitalizations related to these conditions.
RESULTS: Eligible participants before and after propensity-score matching were 104,066 and 31,839, respectively (no treatment n=7,146; colchicine only n=7,146; statin only n=9,030; concomitant therapy n=8,517). Compared with no treatment, CK elevations >3× ULN were observed with statin therapy (HR 1.64, 95% CI 1.39-1.93) and concomitant colchicine-statin therapy (HR 1.74, 95% CI 1.44-2.09), but not with colchicine therapy alone (HR 1.08, 95% CI 0.89-1.31). Clinically diagnosed myopathy was infrequent and showed a graded increase across exposure groups, with the highest risk observed in the concomitant treatment group (HR 1.50, 95% CI 1.31-1.72).
CONCLUSION: Although colchicine-statin concomitant therapy was associated with higher rates of laboratory and clinical adverse events, the additional risk beyond statin monotherapy was small, supporting their use when clinically indicated.